NO2020038I1 - Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt - Google Patents

Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt

Info

Publication number: NO2020038I1
Authority: NO; Norway
Prior art keywords: ozanimod; pharmaceutically acceptable; salt; acceptable salt; hydrochloride salt
Prior art date: 2008-12-22

Application number

NO2020038C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-22

Filing date

2020-11-18

Publication date

2020-11-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2020038(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-11-18 Application filed by Novartis Ag filed Critical Novartis Ag

2020-11-18 Publication of NO2020038I1 publication Critical patent/NO2020038I1/no

Links

QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 title 1
XRVDGNKRPOAQTN-FQEVSTJZSA-N 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)=NO1 XRVDGNKRPOAQTN-FQEVSTJZSA-N 0.000 title 1
229950008141 ozanimod Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO2020038C 2008-12-22 2020-11-18 Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt NO2020038I1 (no)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US13967208P	2008-12-22	2008-12-22
US21853009P	2009-06-19	2009-06-19
US24671509P	2009-09-29	2009-09-29
EP09797234.3A EP2379067B1 (en)	2008-12-22	2009-12-21	Dosage regimen for fingolimod for the treatment of multiple sclerosis
EP15158251.7A EP2907511A1 (en)	2008-12-22	2009-12-21	Dosage regimen for a s1p receptor agonist
EP16182876.9A EP3120844A1 (en)	2008-12-22	2009-12-21	Dosage regimen for a s1p receptor agonist
PCT/US2009/068888 WO2010075239A1 (en)	2008-12-22	2009-12-21	Dosage regimen for a s1p receptor agonist

Publications (1)

Publication Number	Publication Date
NO2020038I1 true NO2020038I1 (no)	2020-11-18

Family

ID=41667217

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO2020038C NO2020038I1 (no)	2008-12-22	2020-11-18	Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt

Country Status (42)

Country	Link
US (11)	US20100160259A1 (no)
EP (7)	EP3409274B1 (no)
JP (7)	JP2012513401A (no)
KR (1)	KR101347919B1 (no)
CN (1)	CN102264359A (no)
AR (1)	AR074826A1 (no)
AU (1)	AU2009330176C9 (no)
BR (1)	BRPI0923500A2 (no)
CA (1)	CA2747802C (no)
CL (2)	CL2011001529A1 (no)
CO (1)	CO6390117A2 (no)
CR (1)	CR20110274A (no)
CU (1)	CU20110136A7 (no)
CY (4)	CY1116990T1 (no)
DK (3)	DK3409274T3 (no)
EA (1)	EA201100978A1 (no)
EC (1)	ECSP11011222A (no)
ES (3)	ES2760607T3 (no)
FR (1)	FR20C1060I1 (no)
HN (1)	HN2011001759A (no)
HR (3)	HRP20151190T1 (no)
HU (4)	HUE052048T2 (no)
IL (3)	IL213170A0 (no)
LT (3)	LT3453387T (no)
LU (1)	LUC00183I2 (no)
MA (1)	MA32981B1 (no)
ME (2)	ME03594B (no)
MX (2)	MX2011006623A (no)
NO (1)	NO2020038I1 (no)
NZ (1)	NZ593065A (no)
PE (1)	PE20120337A1 (no)
PL (3)	PL2379067T3 (no)
PT (3)	PT2379067E (no)
RS (2)	RS59857B1 (no)
SG (1)	SG171404A1 (no)
SI (3)	SI2379067T1 (no)
SM (2)	SMT202000054T1 (no)
TN (1)	TN2011000272A1 (no)
TW (1)	TW201028143A (no)
UY (1)	UY32352A (no)
WO (1)	WO2010075239A1 (no)
ZA (2)	ZA201103863B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101718639B1 (ko) *	2008-03-17	2017-03-21	액테리온 파마슈티칼 리미티드	선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
SI2379067T1 (sl)	2008-12-22	2016-01-29	Novartis Ag	Režim odmerjanja fingolimoda za zdravljenje multiple skleroze
EP3047848A1 (en)	2009-09-29	2016-07-27	Novartis AG	Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) *	2009-11-20	2011-05-26	Shreeram Aradhye	Use of an S1P Receptor Agonist
CN103221391B (zh)	2010-01-27	2018-07-06	艾尼纳制药公司	(R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法
AU2011249789B2 (en) *	2010-05-06	2015-03-19	Novartis Ag	Dosage regimen of diaryl sulfide derivatives
EP2455080A1 (en) *	2010-11-23	2012-05-23	Almirall, S.A.	S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr)	2010-12-13	2013-12-27	Centre Nat Rech Scient	Inhibiteurs des infections a vih et leurs utilisations
UA114283C2 (uk)	2011-01-07	2017-05-25	Новартіс Аг	Композиції імуносупресантів
EP2675893B1 (en)	2011-02-18	2019-01-09	The Scripps Research Institute	Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
JO3177B1 (ar)	2011-04-01	2018-03-08	Novartis Ag	تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
US9592268B2 (en)	2011-05-23	2017-03-14	Cornell University	Endothelium protective materials and methods of use
TW201320994A (zh) *	2011-10-11	2013-06-01	Novartis Ag	投藥療程
DK2885266T3 (da)	2012-08-17	2020-06-08	Actelion Pharmaceuticals Ltd	Fremgangsmåde til fremstilling af (2z,5z)-5-(3-chlor-4-((r)-2,3-dihydroxypropoxy)benzyliden)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-on og mellemprodukt, der anvendes i fremgangsmåden
WO2014138502A1 (en) *	2013-03-06	2014-09-12	Acorda Therapeutics, Inc.	Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
US10675254B2 (en)	2013-10-11	2020-06-09	Teikoku Seiyaku Co., Ltd.	Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
JP6401257B2 (ja)	2013-10-11	2018-10-10	テイコクファーマユーエスエーインコーポレーテッド	局所用スフィンゴシン−１−リン酸受容体アゴニスト製剤及びその使用方法
CN106456552A (zh) *	2014-04-10	2017-02-22	诺华股份有限公司	S1p调节剂的立即释放剂量方案
TW201625242A (zh)	2014-12-11	2016-07-16	艾克泰聯製藥有限公司	選擇性ｓ１ｐ受體激動劑之給藥方案
NZ734220A (en) *	2015-01-06	2022-01-28	Arena Pharm Inc	Methods of treating conditions related to the s1p1 receptor
US20180042895A1 (en)	2015-02-26	2018-02-15	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
MA42807A (fr)	2015-06-22	2018-07-25	Arena Pharm Inc	Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
KR20190113955A (ko)	2017-02-16	2019-10-08	아레나 파마슈티칼스, 인크.	장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CA3053418A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
AU2019280822A1 (en)	2018-06-06	2021-01-07	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
AU2020372647A1 (en)	2019-10-31	2022-06-16	Idorsia Pharmaceuticals Ltd	Combination of a CXCR7 antagonist with an S1P1 receptor modulator
WO2021158838A1 (en)	2020-02-07	2021-08-12	Argentum Pharmaceuticals Llc	Dosage regimen of an s1p receptor modulator
WO2021158848A1 (en) *	2020-02-07	2021-08-12	Argentum Pharmaceuticals Llc	Dosage regimen of an s1p receptor agonist
CN113332435B (zh) *	2021-06-18	2022-10-18	广州中医药大学(广州中医药研究院)	鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0627406T3 (da)	1992-10-21	1999-07-12	Taito Co	2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
CA2421893A1 (en)	2000-08-31	2002-03-07	Merck And Co., Inc.	Phosphate derivatives as immunoregulatory agents
BR0311173A (pt)	2002-05-16	2005-03-15	Novartis Ag	Uso de agentes de ligação do receptor de edg em câncer
CA2539033C (en) *	2003-09-12	2013-03-05	Neuronova Ab	Treatment of disease or injury of the nervous system with fty720
US20060002999A1 (en) *	2004-06-17	2006-01-05	Forest Laboratories, Inc.	Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
SG158096A1 (en) *	2004-11-29	2010-01-29	Novartis Ag	Dosage regimen of an s1p receptor agonist
EP1688141A1 (en) *	2005-01-31	2006-08-09	elbion AG	The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP1850689A4 (en) *	2005-02-10	2013-05-22	G I View Ltd	TECHNIQUES FOR DISPLACING A GASTROINTESTINAL TOOL EQUIPPED WITH A GUIDING ELEMENT
PL2465492T3 (pl) *	2007-10-12	2015-11-30	Novartis Ag	Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P)
KR101718639B1 (ko)	2008-03-17	2017-03-21	액테리온 파마슈티칼 리미티드	선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
KR20170081755A (ko) *	2008-06-20	2017-07-12	노파르티스 아게	다발성 경화증을 치료하기 위한 소아용 조성물
SI2379067T1 (sl)	2008-12-22	2016-01-29	Novartis Ag	Režim odmerjanja fingolimoda za zdravljenje multiple skleroze
BRPI0923213A2 (pt)	2008-12-22	2016-01-26	Novaris Ag	regime de dosagem de um agonista do receptor para s1p.

2009
- 2009-12-21 SI SI200931311T patent/SI2379067T1/sl unknown
- 2009-12-21 SI SI200932015T patent/SI3409274T1/sl unknown
- 2009-12-21 ES ES18179301T patent/ES2760607T3/es active Active
- 2009-12-21 LT LTEP18201062.9T patent/LT3453387T/lt unknown
- 2009-12-21 LT LTEP18179301.9T patent/LT3409274T/lt unknown
- 2009-12-21 SG SG2011037629A patent/SG171404A1/en unknown
- 2009-12-21 HU HUE18201062A patent/HUE052048T2/hu unknown
- 2009-12-21 KR KR1020117017073A patent/KR101347919B1/ko active IP Right Grant
- 2009-12-21 EP EP18179301.9A patent/EP3409274B1/en not_active Revoked
- 2009-12-21 HU HUE09797234A patent/HUE026869T2/en unknown
- 2009-12-21 EA EA201100978A patent/EA201100978A1/ru unknown
- 2009-12-21 WO PCT/US2009/068888 patent/WO2010075239A1/en active Application Filing
- 2009-12-21 RS RS20191546A patent/RS59857B1/sr unknown
- 2009-12-21 HU HUE18179301A patent/HUE048717T4/hu unknown
- 2009-12-21 DK DK18179301.9T patent/DK3409274T3/da active
- 2009-12-21 ES ES18201062T patent/ES2810823T3/es active Active
- 2009-12-21 EP EP09797234.3A patent/EP2379067B1/en not_active Revoked
- 2009-12-21 PT PT97972343T patent/PT2379067E/pt unknown
- 2009-12-21 EP EP15158251.7A patent/EP2907511A1/en not_active Withdrawn
- 2009-12-21 AR ARP090105010A patent/AR074826A1/es not_active Application Discontinuation
- 2009-12-21 ME MEP-2019-339A patent/ME03594B/me unknown
- 2009-12-21 PT PT182010629T patent/PT3453387T/pt unknown
- 2009-12-21 SM SM20200054T patent/SMT202000054T1/it unknown
- 2009-12-21 MA MA34034A patent/MA32981B1/fr unknown
- 2009-12-21 DK DK18201062.9T patent/DK3453387T3/da active
- 2009-12-21 PL PL09797234T patent/PL2379067T3/pl unknown
- 2009-12-21 RS RS20200900A patent/RS60666B1/sr unknown
- 2009-12-21 CN CN2009801518640A patent/CN102264359A/zh active Pending
- 2009-12-21 PL PL18201062T patent/PL3453387T3/pl unknown
- 2009-12-21 CA CA2747802A patent/CA2747802C/en active Active
- 2009-12-21 BR BRPI0923500-0A patent/BRPI0923500A2/pt not_active Application Discontinuation
- 2009-12-21 PE PE2011001265A patent/PE20120337A1/es not_active Application Discontinuation
- 2009-12-21 TW TW098143960A patent/TW201028143A/zh unknown
- 2009-12-21 NZ NZ593065A patent/NZ593065A/xx not_active IP Right Cessation
- 2009-12-21 SI SI200932080T patent/SI3453387T1/sl unknown
- 2009-12-21 EP EP18201062.9A patent/EP3453387B1/en active Active
- 2009-12-21 US US12/642,892 patent/US20100160259A1/en not_active Abandoned
- 2009-12-21 EP EP22187007.4A patent/EP4098256B1/en active Active
- 2009-12-21 PT PT181793019T patent/PT3409274T/pt unknown
- 2009-12-21 JP JP2011542521A patent/JP2012513401A/ja not_active Withdrawn
- 2009-12-21 PL PL18179301T patent/PL3409274T3/pl unknown
- 2009-12-21 DK DK09797234.3T patent/DK2379067T3/en active
- 2009-12-21 EP EP16182876.9A patent/EP3120844A1/en not_active Withdrawn
- 2009-12-21 ME MEP-2020-156A patent/ME03802B/me unknown
- 2009-12-21 MX MX2011006623A patent/MX2011006623A/es unknown
- 2009-12-21 ES ES09797234.3T patent/ES2552823T3/es active Active
- 2009-12-21 UY UY0001032352A patent/UY32352A/es not_active Application Discontinuation
- 2009-12-21 SM SM20200441T patent/SMT202000441T1/it unknown
- 2009-12-21 AU AU2009330176A patent/AU2009330176C9/en not_active Withdrawn - After Issue
- 2009-12-21 US US13/141,552 patent/US20110257133A1/en not_active Abandoned
- 2009-12-21 EP EP20160225.7A patent/EP3677260A1/en active Pending
2011
- 2011-05-25 ZA ZA2011/03863A patent/ZA201103863B/en unknown
- 2011-05-25 CR CR20110274A patent/CR20110274A/es not_active Application Discontinuation
- 2011-05-26 TN TN2011000272A patent/TN2011000272A1/fr unknown
- 2011-05-26 IL IL213170A patent/IL213170A0/en unknown
- 2011-06-17 MX MX2021010759A patent/MX2021010759A/es unknown
- 2011-06-21 CL CL2011001529A patent/CL2011001529A1/es unknown
- 2011-06-22 CU CU20110136A patent/CU20110136A7/es unknown
- 2011-06-22 HN HN2011001759A patent/HN2011001759A/es unknown
- 2011-06-22 EC EC2011011222A patent/ECSP11011222A/es unknown
- 2011-06-23 CO CO11079290A patent/CO6390117A2/es not_active Application Discontinuation
2012
- 2012-08-06 ZA ZA2012/05942A patent/ZA201205942B/en unknown
2013
- 2013-05-31 CL CL2013001558A patent/CL2013001558A1/es unknown
- 2013-09-06 US US14/020,058 patent/US20140066657A1/en not_active Abandoned
2014
- 2014-01-31 US US14/169,660 patent/US20140148415A1/en not_active Abandoned
- 2014-04-10 JP JP2014080892A patent/JP2014144970A/ja not_active Withdrawn
2015
- 2015-10-14 JP JP2015202669A patent/JP2016135752A/ja not_active Withdrawn
- 2015-11-06 HR HRP20151190TT patent/HRP20151190T1/hr unknown
- 2015-11-30 CY CY20151101084T patent/CY1116990T1/el unknown
- 2015-12-02 US US14/956,855 patent/US20160081949A1/en not_active Abandoned
2016
- 2016-05-23 US US15/161,778 patent/US20160263061A1/en not_active Abandoned
2017
- 2017-03-06 JP JP2017041331A patent/JP2017141238A/ja not_active Withdrawn
- 2017-03-21 US US15/465,091 patent/US20170189353A1/en not_active Abandoned
2018
- 2018-06-11 US US16/005,137 patent/US20180289638A1/en not_active Abandoned
- 2018-11-26 US US16/199,905 patent/US20190091180A1/en not_active Abandoned
2019
- 2019-05-22 JP JP2019095899A patent/JP7329965B2/ja active Active
- 2019-12-02 HR HRP20192175TT patent/HRP20192175T1/hr unknown
- 2019-12-03 CY CY20191101264T patent/CY1122812T1/el unknown
2020
- 2020-05-05 US US16/867,293 patent/US20200330407A1/en not_active Abandoned
- 2020-05-18 IL IL274756A patent/IL274756A/en unknown
- 2020-07-27 HR HRP20201167TT patent/HRP20201167T1/hr unknown
- 2020-08-03 CY CY20201100712T patent/CY1123255T1/el unknown
- 2020-11-17 LU LU00183C patent/LUC00183I2/fr unknown
- 2020-11-17 LT LTPA2020005C patent/LTPA2020005I1/lt unknown
- 2020-11-18 NO NO2020038C patent/NO2020038I1/no unknown
- 2020-11-19 FR FR20C1060C patent/FR20C1060I1/fr active Active
- 2020-11-19 HU HUS2000046C patent/HUS2000046I1/hu unknown
- 2020-11-19 CY CY2020036C patent/CY2020036I2/el unknown
- 2020-11-23 IL IL278914A patent/IL278914A/en unknown
2021
- 2021-09-20 US US17/479,649 patent/US20220142949A1/en not_active Abandoned
2022
- 2022-04-21 JP JP2022070231A patent/JP2022103194A/ja active Pending
2024
- 2024-06-06 JP JP2024092377A patent/JP2024129030A/ja active Pending

Also Published As

Publication number	Publication date
EP2379067A1 (en)	2011-10-26
HUE048717T4 (hu)	2022-02-28
RS59857B1 (sr)	2020-02-28
SMT202000441T1 (it)	2020-09-10
PL3453387T3 (pl)	2020-11-02
KR101347919B1 (ko)	2014-01-07
CY1122812T1 (el)	2021-05-05
SI3453387T1 (sl)	2020-10-30
AR074826A1 (es)	2011-02-16
ME03802B (me)	2021-04-20
PL3409274T3 (pl)	2020-06-01
LTPA2020005I1 (lt)	2020-12-10
BRPI0923500A2 (pt)	2018-05-29
HUE048717T2 (hu)	2020-08-28
IL274756A (en)	2020-07-30
JP2024129030A (ja)	2024-09-26
PT3409274T (pt)	2019-12-17
ZA201205942B (en)	2013-03-27
KR20110096175A (ko)	2011-08-29
SI2379067T1 (sl)	2016-01-29
HUE026869T2 (en)	2016-08-29
CY2020036I2 (el)	2021-06-25
AU2009330176B2 (en)	2014-03-06
HUE052048T2 (hu)	2021-04-28
EP3677260A1 (en)	2020-07-08
PE20120337A1 (es)	2012-04-24
ECSP11011222A (es)	2011-08-31
RS60666B1 (sr)	2020-09-30
AU2009330176A1 (en)	2011-07-07
CR20110274A (es)	2011-07-19
US20200330407A1 (en)	2020-10-22
US20110257133A1 (en)	2011-10-20
JP7329965B2 (ja)	2023-08-21
ES2810823T3 (es)	2021-03-09
EP4098256B1 (en)	2025-02-26
CY1116990T1 (el)	2017-04-05
LUC00183I2 (no)	2024-07-01
IL213170A0 (en)	2011-07-31
DK3409274T3 (da)	2019-12-16
LT3453387T (lt)	2020-08-25
EP4098256A1 (en)	2022-12-07
HUS2000046I1 (hu)	2020-12-28
EP3120844A1 (en)	2017-01-25
EP3409274A1 (en)	2018-12-05
HRP20151190T1 (hr)	2016-01-01
US20160263061A1 (en)	2016-09-15
JP2017141238A (ja)	2017-08-17
PT3453387T (pt)	2020-08-11
US20140066657A1 (en)	2014-03-06
JP2022103194A (ja)	2022-07-07
FR20C1060I1 (fr)	2020-12-25
SG171404A1 (en)	2011-07-28
CY2020036I1 (el)	2021-03-12
HN2011001759A (es)	2013-11-26
HRP20201167T1 (hr)	2020-12-11
LT3409274T (lt)	2020-02-10
US20220142949A1 (en)	2022-05-12
EP3409274B1 (en)	2019-11-20
CL2013001558A1 (es)	2013-10-25
CN102264359A (zh)	2011-11-30
AU2009330176C9 (en)	2017-01-05
US20180289638A1 (en)	2018-10-11
ZA201103863B (en)	2012-10-31
US20170189353A1 (en)	2017-07-06
MX2021010759A (es)	2022-07-19
CU20110136A7 (es)	2012-01-31
DK2379067T3 (en)	2015-12-07
ES2552823T3 (es)	2015-12-02
US20140148415A1 (en)	2014-05-29
CO6390117A2 (es)	2012-02-29
CA2747802A1 (en)	2010-07-01
SI3409274T1 (sl)	2020-03-31
CL2011001529A1 (es)	2012-02-24
AU2009330176C1 (en)	2016-12-08
UY32352A (es)	2010-07-30
IL278914A (en)	2021-01-31
JP2014144970A (ja)	2014-08-14
SMT202000054T1 (it)	2020-03-13
CA2747802C (en)	2021-02-09
JP2012513401A (ja)	2012-06-14
JP2019167360A (ja)	2019-10-03
US20160081949A1 (en)	2016-03-24
WO2010075239A1 (en)	2010-07-01
US20100160259A1 (en)	2010-06-24
CY1123255T1 (el)	2021-10-29
EP3453387B1 (en)	2020-06-03
MX2011006623A (es)	2011-07-12
EA201100978A1 (ru)	2012-01-30
ES2760607T3 (es)	2020-05-14
NZ593065A (en)	2012-11-30
EP3453387A1 (en)	2019-03-13
TW201028143A (en)	2010-08-01
EP2379067B1 (en)	2015-09-02
PT2379067E (pt)	2015-12-23
EP2907511A1 (en)	2015-08-19
ME03594B (me)	2020-07-20
DK3453387T3 (da)	2020-08-10
PL2379067T3 (pl)	2016-02-29
US20190091180A1 (en)	2019-03-28
JP2016135752A (ja)	2016-07-28
TN2011000272A1 (en)	2012-12-17
MA32981B1 (fr)	2012-01-02
HRP20192175T1 (hr)	2020-03-20

Publication	Publication Date	Title
NO2020038I1 (no)	2020-11-18	Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NO2023047I1 (no)	2023-12-21	Cedazuridine, or a pharmaceutically acceptable salt thereof
NO2020034I1 (no)	2020-09-29	Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid
FIC20240039I1 (fi)	2024-11-12	Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
NO2022057I1 (no)	2022-12-13	Capmatinib or a pharmaceutically acceptable salt thereof
FIC20240026I1 (fi)	2024-07-18	Etrasimodi tai sen farmaseuttisesti hyväksyttävä suola, kuten etrasimodiarginiini
FIC20240046I1 (fi)	2024-12-16	Vibegroni tai sen farmaseuttisesti hyväksyttävä suola
NO2020037I1 (no)	2020-11-16	alpelisib eller et farmasøytisk akseptabelt salt derav
NO2024010I1 (no)	2024-03-06	Gefapixant, or a pharmaceutically acceptable salt thereof
NO2020039I1 (no)	2020-11-18	Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid
NO2019042I1 (no)	2019-11-28	Talazoparib, eventuelt i form av et farmasøytisk aksepterbart salt
NO2024006I1 (no)	2024-02-01	Piflufolastat (18F) or a pharmaceutically acceptable salt thereof
NO2023017I1 (no)	2023-04-27	Mitapivat or a pharmaceutically acceptable salt thereof, in particular mitapivat sulfate
NO2022033I1 (no)	2022-07-22	Rimegepant or a pharmaceutically acceptable salt thereof
NO2020006I1 (no)	2020-03-11	upadacitinib or a pharmaceutically acceptable salt thereof
NL301037I2 (nl)	2020-05-12	Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NO2019024I1 (no)	2019-05-20	Brigatinib eller et farmasøytisk akseptabelt salt derav
NO2016016I2 (no)	2016-08-17	Lesinurad, eller et farmasøytisk akseptabelt salt derav
NO2019027I1 (no)	2019-07-04	kobicistat eller et farmasøytisk akseptabelt salt derav
NO2018016I2 (no)	2018-05-14	Niraparib eller et farmasøytisk akseptabelt salt, stereoisomer eller tautomer derav
NL301106I1 (nl)	2021-06-02	Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NO2020018I1 (no)	2020-06-17	Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
NO2017059I1 (no)	2017-11-13	ribosiklib eller et farmasøytisk akseptabelt salt derav
NL301202I2 (nl)	2023-01-24	Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NL300886I2 (nl)	2017-10-24	baricitinib, of een farmaceutisch aanvaardbaar zout daarvan